$220m market cap/$127m cash...possible blockbuster drug in two ph3 trials...so basically Tivatinib is now worth what DS and KK originally paid $60m and $30m. I don't get it!
Low float, that's all there to it! Insiders are nibbling here. I want to also but know I better wait till mid to end Oct. 6 to 7 again in Jan unless bad news.
Well, ARQL made it back to 5 and not 3. Heavy trading today vs. its 3 month average. I listened to the last investor conference. No new news. It was a somewhat awkward start to the conference. The CEO is not a dynamic speaker, and his accent makes him somewhat difficult to understand.